After the inspection, the FDA issued a Form 483 with five observations. Biocon said these observations are procedural in nature and do not relate to data integrity, systemic non-compliance, or quality oversight. Shares of Biocon Ltd ended at ₹357.50, down by ₹4.05 or 1.12%, on the BSE today (Sept 4).
